Table 2 Demographic information for the Shoklo Malaria Research Unit (SMRU) severe malaria diagnostic groups and the Mahidol-Oxford Tropical Medicine Research Unit (MORU) / Oxford University Clinical Research Unit (OUCRU) hospitalised patients
From: Severe falciparum malaria in pregnancy in Southeast Asia: a multi-centre retrospective cohort study
Characteristic | SMRU | MORU/OUCRU | ||
|---|---|---|---|---|
Severe malaria with vital organ dysfunction (n = 38) | Severe malaria with hyperparasitaemia only (n = 50) | Severe malaria with severe anaemia only (n = 35) | Hospitalised severe malaria (n = 90) | |
Age (years) | 27 [18–35] | 23.5 [19–29] | 25 [20–33] | 25 [22–30] (n = 56) |
Trimester | ||||
First | 11% (4/38) | 18% (9/50) | 14% (5/35) | 9% (4/46) |
Second | 32% (12/38) | 40% (20/50) | 51% (18/35) | 46% (21/46) |
Third | 50% (19/38) | 42% (21/50) | 34% (12/35) | 46% (21/46) |
Postpartum | 8% (3/38)a | 0 | 0 | 0 |
EGA (week) | 30.4 [23.0–34.2] | 25.4 [18.1–32.3] | 23.9 [16.5–30.2] | 26 [21.4–32] (n = 46) |
Parity | 2 [0–3] | 1 [0–2] | 1 [0–3] | No data |
Gravidity | 3 [1–5] | 2 [1–3] | 2 [1–4] | No data |
Body weight (kg) | 50 [45–54] | 49 [44–52] (n = 49) | 46 [42–53] | 50 [44.5–54.5] (n = 88) |
Fever > 37.5 °C on admissionb | 55% (16/29) | 45% (21/47) | 53% (18/34) | 60% (44/73) |
Days of fever | 3 [2–5] (n = 29) | 3 [2–4] (n = 48) | 4 [1–5] | 6 [4–8] (n = 49) |
Species | ||||
Pf mono-infection | 91% (32/35) | 92% (46/50) | 89% (31/35) | No data |
Pf + Pv coinfection | 9% (3/35) | 8% (4/50) | 12% (4/35) | |
Asexual parasitaemia load (/µL) | 179,357 [112,538–372,655] (n = 31) | 465,850 [409,958–531,288] | 42,001 [16,052–64,433] | 60,288 [13,188–31,6512] (n = 81) |
Proportion of infected red blood cells (%) | 5.4 [3.2–12.2] (n = 31) | 12 [10.6–15.1] | 2 [0.8–2.7] | 2.1 [0.6–12.3] (n = 81) |
Gametocytaemia | 45% (14/31) | 22% (11/50) | 23% (8/35) | 50% (7/14) |
Schizontaemia | 29% (9/31) | 16% (8/50) | 0% (0/35) | No data |
Malaria pigment | 87% (20/23) | 79% (30/38) | 33% (6/18) | 89% (47/53)c |
Haematocrit (%) | 25 [19–29.5] (n = 28) | 29 [25–33] (n = 48) | 17 [16–18] | 21 [17–26] (n = 73) |
No previous ANC visits | 32% (12/38) | 28% (14/50) | 37% (13/35) | No data |
Days since last ANCd | 14 [10–25] (n = 26) | 13.5 [9–26.5] (n = 36) | 18 [7–35] (n = 22) | No data |
Treatment | ||||
IV/IM artesunate | 71% (24/34) | 18% (9/50) | 3% (1/35) | 34% (31/90) |
IV/IM artemether | 13% (4/34) | 0 | 0 | 17% (15/90) |
IV/IM quinine | 13% (4/34) | 2% (1/50) | 6% (2/35) | 49% (44/90) |
Oral ABT | 0 | 58% (29/50) | 66% (23/35) | 0 |
Oral ABT + rescue IV | 6% (2/34) | 20% (10/50) | 0 | 0 |
Oral quinine | 0 | 2% (1/50) | 26% (9/35) | 0 |